|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for GLRX |
 Gene summary |
| Basic gene Info. | Gene symbol | GLRX |
| Gene name | glutaredoxin (thioltransferase) | |
| Synonyms | GRX|GRX1 | |
| Cytomap | UCSC genome browser: 5q14 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001118890.1, NM_001243658.1,NM_001243659.1,NM_002064.2, | |
| Description | TTase-1glutaredoxin-1thioltransferase-1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 600443 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000173221 | ||
| HPRD : 02707 | ||
| Vega : OTTHUMG00000121167 | ||
| Protein | UniProt: P35754 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_GLRX | |
| BioGPS: 2745 | ||
| Pathway | NCI Pathway Interaction Database: GLRX | |
| KEGG: GLRX | ||
| REACTOME: GLRX | ||
| Pathway Commons: GLRX | ||
| Context | iHOP: GLRX | |
| ligand binding site mutation search in PubMed: GLRX | ||
| UCL Cancer Institute: GLRX | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0045838 | positive regulation of membrane potential | 19542013 | GO:2000651 | positive regulation of sodium ion transmembrane transporter activity | 19542013 |
| Top |
| Ligand binding site mutations for GLRX |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C83 | G82R | UCEC | 1 | P71 | R72Q | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for GLRX |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | P71 | R72Q | -1.4219156 | C83 | G82R | -0.92893465 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for GLRX from PDB |
| Top |
| Differential gene expression and gene-gene network for GLRX |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for GLRX |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for GLRX |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|nutraceutical | DB00143 | Glutathione | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of GLRX go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of GLRX |
| Multiple alignments for P35754 in multiple species |
| LBS | AA sequence | # species | Species | C83 | DCIGGCSDLVS | 1 | Homo sapiens | C83 | KCIGGFSDLQK | 1 | Gallus gallus | C83 | ECIGGCTDLVN | 1 | Bos taurus | C83 | DCIGGCSDLLS | 1 | Rattus norvegicus | C83 | DCIGGCSDLIS | 1 | Mus musculus | P71 | GARTVPRVFIG | 4 | Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus | P71 | GQRTVPRVFIG | 1 | Gallus gallus | Q58 | HTNEIQDYLQQ | 1 | Homo sapiens | Q58 | -MDDIQDYFQK | 1 | Gallus gallus | Q58 | NISEIQDYLQQ | 1 | Bos taurus | Q58 | NTNAIQDYLQQ | 1 | Rattus norvegicus | Q58 | NTSAIQDYLQQ | 1 | Mus musculus | R68 | QLTGARTVPRV | 4 | Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus | R68 | KTTGQRTVPRV | 1 | Gallus gallus | S84 | CIGGCSDLVSL | 1 | Homo sapiens | S84 | CIGGFSDLQKM | 1 | Gallus gallus | S84 | CIGGCTDLVNM | 1 | Bos taurus | S84 | CIGGCSDLLSM | 1 | Rattus norvegicus | S84 | CIGGCSDLISM | 1 | Mus musculus | T69 | LTGARTVPRVF | 4 | Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus | T69 | TTGQRTVPRVF | 1 | Gallus gallus | V70 | TGARTVPRVFI | 4 | Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus | V70 | TGQRTVPRVFI | 1 | Gallus gallus | V87 | GCSDLVSLQQS | 1 | Homo sapiens | V87 | GFSDLQKMEQ- | 1 | Gallus gallus | V87 | GCTDLVNMHER | 1 | Bos taurus | V87 | GCSDLLSMQQN | 1 | Rattus norvegicus | V87 | GCSDLISMQQT | 1 | Mus musculus | Y25 | KPTCPYCRKTQ | 3 | Bos taurus, Rattus norvegicus, Mus musculus | Y25 | KPTCPYCRRAQ | 1 | Homo sapiens | Y25 | KGSCPYCKNAI | 1 | Gallus gallus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |